



29 June 2017

ASX ANNOUNCEMENT

ImpediMed Commences Commercial Sales of SOZO™

Brisbane, Australia and Carlsbad, Calif.- ImpediMed Limited (ASX: IPD) a global provider of medical technology to non-invasively measure, monitor and manage fluid status and body composition, is pleased to announce it has commenced its targeted launch of its SOZO™ platform in Europe and Australia, with first commercial sales and shipments underway.

The initial phase of the launch, which follows the recent receipt of CE Mark, is focused on converting existing customers to the latest technology and targeting new installations at large, multidisciplinary hospitals.

Large hospital systems will be the first customers to use SOZOhub, ImpediMed's enterprise software, to connect devices for various fluid and body composition indications.

"We are very excited to see the first initial sales of SOZO™ so soon after receiving CE Mark," said Richard Carreon, Managing Director and CEO of ImpediMed."

"The initial launch of SOZO™ and our new suite of software products will provide us invaluable clinician and patient feedback, both from single site usage up through large hospital enterprise systems. The experience gained from this phase will allow us to move to a broader commercial launch in the coming months and ultimately prepare us for the US introduction slated for later this calendar year."

Richard Carreon
Managing Director & CEO

For further information, contact:

Richard Carreon, ImpediMed Managing Director & CEO
Morten Vigeland, ImpediMed CFO
T: +1 (760) 585-2100

Media Contact:

Kyahn Williamson, WE Buchan
T: +61 3 9866 4722
E: kwilliamson@buchanwe.com.au

About ImpediMed

Founded and headquartered in Brisbane, Australia with U.S. offices in Carlsbad, Calif. and Bloomington, Minn., and a European office in Thessaloniki, Greece, ImpediMed is the world leader in the design and manufacture of medical devices employing bioimpedance spectroscopy (BIS) technologies for use in the non-invasive clinical assessment and monitoring of tissue composition and fluid status.

ImpediMed was the first company to receive FDA clearance in the U.S. to aid healthcare professionals to clinically assess unilateral lymphoedema of the arm and leg in women and the leg in men, for its L-Dex[®] device. In addition, ImpediMed produces a family of CE Marked medical devices, including SOZO[™], sold in select markets globally.

For more information, visit www.impedimed.com.